Future Fund LLC Takes $608,000 Position in RxSight, Inc. $RXST

Future Fund LLC acquired a new position in RxSight, Inc. (NASDAQ:RXST) in the 2nd quarter, HoldingsChannel reports. The fund acquired 46,749 shares of the company’s stock, valued at approximately $608,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Carnegie Lake Advisors LLC purchased a new stake in shares of RxSight during the 2nd quarter valued at approximately $1,391,000. Y Intercept Hong Kong Ltd bought a new position in shares of RxSight in the second quarter worth $1,431,000. Bessemer Group Inc. purchased a new position in shares of RxSight in the second quarter valued at $33,000. CWM LLC raised its stake in shares of RxSight by 614.1% during the 2nd quarter. CWM LLC now owns 4,520 shares of the company’s stock valued at $59,000 after purchasing an additional 3,887 shares during the period. Finally, Tempus Wealth Planning LLC raised its stake in shares of RxSight by 109.2% during the 2nd quarter. Tempus Wealth Planning LLC now owns 22,565 shares of the company’s stock valued at $293,000 after purchasing an additional 11,777 shares during the period. 78.78% of the stock is currently owned by institutional investors.

RxSight Price Performance

Shares of RxSight stock opened at $9.37 on Monday. RxSight, Inc. has a 1 year low of $6.32 and a 1 year high of $49.25. The firm has a market cap of $385.29 million, a PE ratio of -10.65 and a beta of 1.16. The company has a 50 day simple moving average of $8.78 and a two-hundred day simple moving average of $10.72.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.15. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. The firm had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $25.63 million. During the same quarter last year, the company posted ($0.16) EPS. The business’s quarterly revenue was down 31.4% on a year-over-year basis. RxSight has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on RXST shares. JPMorgan Chase & Co. lifted their target price on RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Thursday. UBS Group reduced their price objective on shares of RxSight from $16.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. Needham & Company LLC upped their target price on shares of RxSight from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of RxSight in a report on Wednesday, October 8th. Finally, Morgan Stanley lowered shares of RxSight from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $20.00 to $9.00 in a research report on Tuesday, July 15th. One equities research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, RxSight currently has a consensus rating of “Reduce” and an average price target of $9.56.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.